Europe's Pharma Industry Faces Challenges Amid Global Competition
Europe's pharmaceutical sector risks lagging behind the U.S. and China due to regulatory hurdles and pricing policies. Roche and Sanofi are committed to launching new drugs across Europe despite challenges. Governmental policies, such as the U.S.' 'most-favored-nation' pricing push, significantly impact European drug launches and innovation.
Europe's pharmaceutical industry is under strain as it risks trailing the U.S. and China, warned Roche CEO Thomas Schinecker, citing 'mind-blowing' bureaucracy as a major hurdle.
This warning follows U.S. President Trump's policy linking American drug prices to cheaper alternatives abroad, significantly affecting European launches.
Despite acknowledging the challenges, industry leaders from Roche and Sanofi emphasize their commitment to introducing new drugs in Europe, negotiating pricing strategies to sustain innovation and market access.
ALSO READ
-
Fast-Tracking Innovation: New Medicare Pathway for Medical Devices
-
Forging An Innovation Future: The Indo-UK Life Sciences Corridor
-
VP Calls on AIIMS Rishikesh Graduates to Lead with Compassion, Innovation and National Service
-
Redwood Software Elevates AI Innovation with New Global Center
-
EU Antitrust Revamp: Innovation Shield for Startups
Google News